Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Strong Revenue Growth, R&D Spending in Q3

NEW YORK, Nov. 1 - Ciphergen Biosystems yesterday reported nearly two-fold growth in revenues and R&D spending during the third quarter amid a slightly widened net loss.


Revenues for the period ended Sept. 30 swelled to $10.2 million from $5.4 million one year ago.


R&D spending mirrored the revenue increase, jumping to $6.0 million from $3.3 million in the third quarter 2001.


As a result, net loss widened to $7.9 million, or $.29, from $6.9 million, or $.26, year over year, Ciphergen said.


The company said it had $51.6 million a year in cash, cash equivalents, and investments in securities as of Sept. 30.


Click here for more information.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.